INT173087

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.62
First Reported 2003
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 5
Total Number 17
Disease Relevance 8.44
Pain Relevance 0.67

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

nucleus (VHLL)
Anatomy Link Frequency
proximal 1
central nervous system 1
VHLL (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 42 97.28 Very High Very High Very High
Central nervous system 2 94.76 High High
Pain 27 70.00 Quite High
antagonist 1 53.68 Quite High
cytokine 17 5.00 Very Low Very Low Very Low
Inflammation 6 5.00 Very Low Very Low Very Low
imagery 4 5.00 Very Low Very Low Very Low
Chronic pancreatitis 3 5.00 Very Low Very Low Very Low
cva 2 5.00 Very Low Very Low Very Low
fibrosis 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Von Hippel-lindau Syndrome 9 100.00 Very High Very High Very High
Cancer 122 99.84 Very High Very High Very High
Coronavirus Infection 46 99.74 Very High Very High Very High
Hypersensitivity 338 98.14 Very High Very High Very High
Hypoxia 52 98.08 Very High Very High Very High
Sprains And Strains 523 97.76 Very High Very High Very High
Headache 42 97.28 Very High Very High Very High
Carcinoma 1 97.20 Very High Very High Very High
Severe Acute Respiratory Syndrome 179 96.24 Very High Very High Very High
Immunization 94 96.24 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
The H5 VLP vaccine was produced as described in D'Aoust et al [6].
Gene_expression (produced) of H5 VLP
1) Confidence 0.62 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008737 Disease Relevance 0.18 Pain Relevance 0
In a second report, we demonstrated that the first doses of a plant-made VLP candidate vaccine can be produced within 3 weeks of the identification of a new pandemic strain [5].
Gene_expression (produced) of VLP associated with sprains and strains
2) Confidence 0.54 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008737 Disease Relevance 0.43 Pain Relevance 0
The H5 VLP vaccine provides cross-clade protection in ferrets
Gene_expression (vaccine) of H5 VLP
3) Confidence 0.54 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008737 Disease Relevance 0.25 Pain Relevance 0
Safety and reactogenicity of the H5 VLP vaccine in humans
Gene_expression (vaccine) of H5 VLP
4) Confidence 0.54 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008737 Disease Relevance 0.50 Pain Relevance 0.13
Immunogenicity of the H5 VLP vaccine in humans
Gene_expression (vaccine) of H5 VLP
5) Confidence 0.54 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008737 Disease Relevance 0.48 Pain Relevance 0.33
Our plant-produced H5 VLP vaccine has the potential to respond to both of these deficiencies.
Gene_expression (produced) of H5 VLP
6) Confidence 0.54 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008737 Disease Relevance 0.21 Pain Relevance 0
This randomized, double-blind, placebo-controlled Phase I clinical trial was performed at the McGill University Health Centre (MUHC) Vaccine Study Center, (Pierrefonds, QC) to assess the safety and immunogenicity of the plant-produced H5 VLP vaccine (registered at ClinicalTrials.gov: NCT00984945).
Gene_expression (produced) of H5 VLP
7) Confidence 0.54 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008737 Disease Relevance 0.27 Pain Relevance 0
There have been no safety signals in the preclinical studies of our candidate H5 VLP vaccine (mice, rats, ferrets) and there were no statistical differences in the incidence or severity of local and systemic reactions between the vaccine and placebo recipients in the Phase I trial reported herein.
Gene_expression (vaccine) of H5 VLP
8) Confidence 0.54 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008737 Disease Relevance 0.30 Pain Relevance 0
Our recently described candidate H5 VLP vaccine produced in plants [5] is a potentially powerful new tool to address these shortcomings.
Gene_expression (produced) of H5 VLP
9) Confidence 0.48 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008737 Disease Relevance 0.57 Pain Relevance 0
In light of these limitations and uncertainties, we used all three serological assays to evaluate the humoral response induced by the plant-made H5 VLP vaccine in humans.
Gene_expression (vaccine) of H5 VLP
10) Confidence 0.47 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008737 Disease Relevance 0.70 Pain Relevance 0
The lack of both allergic reactions and increases in IgE following vaccination may be explained by the fact that the H5 glycans present in this VLP vaccine bear terminal N-acetylglucosamine (GlcNAc). which could conceivably have shielded the more proximal ?
Gene_expression (present) of VLP in proximal associated with hypersensitivity
11) Confidence 0.47 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008737 Disease Relevance 0.45 Pain Relevance 0
The H5 VLP vaccine was well tolerated.
Gene_expression (vaccine) of H5 VLP
12) Confidence 0.47 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008737 Disease Relevance 0.50 Pain Relevance 0.14
H5 VLP vaccine was produced as described above and formulated with 1% Alhydrogel® prior to vaccination (0.5 mg aluminium per 0.5 mL dose).
Gene_expression (produced) of H5 VLP
13) Confidence 0.42 Published 2010 Journal PLoS ONE Section Body Doc Link PMC3008737 Disease Relevance 0.66 Pain Relevance 0
The von Hippel-Lindau protein (pVHL) is the product of the VHL gene, a tumor-suppressor gene known to be inactivated in renal clear-cell carcinomas as well as other markedly vascular tumors such as central nervous system hemangioblastoma [24].
Gene_expression (product) of VHL gene in central nervous system associated with cancer, carcinoma, central nervous system and brain tumor
14) Confidence 0.11 Published 2003 Journal Mol Cancer Section Body Doc Link PMC150383 Disease Relevance 0.62 Pain Relevance 0.05
In well-oxygenated conditions, the VHL gene product pVHL recognizes HIF1?
Gene_expression (product) of VHL gene associated with von hippel-lindau syndrome
15) Confidence 0.06 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2727778 Disease Relevance 1.38 Pain Relevance 0
In the case of the murine coronavirus MHV-A59 the coexpression of the E and M proteins but not the S or N proteins is needed for the release of virus-like particles (VLP) [42].
Gene_expression (coexpression) of VLP associated with coronavirus infection
16) Confidence 0.04 Published 2005 Journal Respir Res Section Body Doc Link PMC548145 Disease Relevance 0.81 Pain Relevance 0
Interestingly, similar RVFV VLP were produced in insect cells infected with a dual baculovirus vector expressing Gn/Gc glycoproteins and the N protein.
Gene_expression (produced) of VLP
17) Confidence 0.02 Published 2010 Journal Veterinary Research Section Body Doc Link PMC2896810 Disease Relevance 0.13 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox